{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:26:32Z","timestamp":1794522392951,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:00:00Z","timestamp":1496448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11011-017-0044-y","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:46:23Z","timestamp":1496450783000},"page":"1529-1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The treatment of juvenile\/adult GM1-gangliosidosis with Miglustat may reverse disease progression"],"prefix":"10.1007","volume":"32","author":[{"given":"Federica","family":"Deodato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Rampazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Taurisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Dionisi-Vici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Caciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,3]]},"reference":[{"key":"44_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","volume":"35","author":"P Alfonso","year":"2005","unstructured":"Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, Sancho J, Pocovi M (2005) Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 35:268\u2013276. doi:\n10.1016\/j.bcmd.2005.05.007","journal-title":"Blood Cells Mol Dis"},{"key":"44_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.pediatrneurol.2008.07.002","volume":"39","author":"R Battini","year":"2008","unstructured":"Battini R et al (2008) Movement disorder-childhood rating scale: reliability and validity. Pediatr Neurol 39:259\u2013265. doi:\n10.1016\/j.pediatrneurol.2008.07.002","journal-title":"Pediatr Neurol"},{"key":"44_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/iub.284","volume":"62","author":"M Beck","year":"2010","unstructured":"Beck M (2010) Therapy for lysosomal storage disorders. IUBMB Life 62:33\u201340. doi:\n10.1002\/iub.284","journal-title":"IUBMB Life"},{"key":"44_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","volume":"34","author":"N Belmatoug","year":"2011","unstructured":"Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM (2011) Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 34:991\u20131001. doi:\n10.1007\/s10545-011-9368-7","journal-title":"J Inherit Metab Dis"},{"key":"44_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","volume":"66","author":"B Bembi","year":"2006","unstructured":"Bembi B et al (2006) Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology 66:278\u2013280. doi:\n10.1212\/01.wnl.0000194225.78917.de","journal-title":"Neurology"},{"key":"44_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri N, Scaglia F (2008) GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 94:391\u2013396. doi:\n10.1016\/j.ymgme.2008.04.012","journal-title":"Mol Genet Metab"},{"key":"44_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00439-003-0930-8","volume":"113","author":"A Caciotti","year":"2003","unstructured":"Caciotti A, Bardelli T, Cunningham J, D'Azzo A, Zammarchi E, Morrone A (2003) Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient. Hum Genet 113:44\u201350. doi:\n10.1007\/s00439-003-0930-8","journal-title":"Hum Genet"},{"key":"44_CR8","doi-asserted-by":"crossref","unstructured":"Caciotti A, Donati MA, Bardell T,d'Azzo A, Massai G, Luciani L, Zammarchi E, Morrone A (2005) Primary and Secondary Elastin-Binding Protein Defect Leads to Impaired Elastogenesis in Fibroblasts from GM1-Gangliosidosis Patients.Am J Pathol 167(6):1689\u20131698","DOI":"10.1016\/S0002-9440(10)61251-5"},{"key":"44_CR9","doi-asserted-by":"crossref","unstructured":"Caciotti A, Donati MA, Procopio E, Filocamo M, Kleijer W, Wuyts W, Blaumeiser B, d'Azzo A, Simi L, Orlando C, McKenzie F, Fiumara A, Zammarchi E, Morrone A (2007) GM1 gangliosidosis: molecular analysis of nine patients and development of an RT-PCR assay for GLB1 gene expression profiling. Hum Mutat 28(2):204\u2013204","DOI":"10.1002\/humu.9475"},{"key":"44_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbadis.2011.03.018","volume":"1812","author":"A Caciotti","year":"2011","unstructured":"Caciotti A et al (2011) GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta 1812:782\u2013790. doi:\n10.1016\/j.bbadis.2011.03.018","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 3","key":"44_CR11","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1007\/s10545-010-9193-4","volume":"33","author":"H Champion","year":"2010","unstructured":"Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, Wraith JE (2010) Dietary modifications in patients receiving miglustat. J Inherit Metab Dis 33(Suppl 3):S379\u2013S383. doi:\n10.1007\/s10545-010-9193-4","journal-title":"J Inherit Metab Dis"},{"key":"44_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.beem.2015.01.001","volume":"29","author":"TM Cox","year":"2015","unstructured":"Cox TM (2015) Innovative treatments for lysosomal diseases. Best Pract Res Clin Endocrinol Metab 29:275\u2013311. doi:\n10.1016\/j.beem.2015.01.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"44_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","volume":"94","author":"E Elliot-Smith","year":"2008","unstructured":"Elliot-Smith E et al (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab 94:204\u2013211. doi:\n10.1016\/j.ymgme.2008.02.005","journal-title":"Mol Genet Metab"},{"key":"44_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13023-015-0240-y","volume":"10","author":"S Fecarotta","year":"2015","unstructured":"Fecarotta S et al (2015) Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C Orphanet. J Rare Dis 10:22. doi:\n10.1186\/s13023-015-0240-y","journal-title":"J Rare Dis"},{"key":"44_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2013.07.019","volume":"110","author":"VM Ginocchio","year":"2013","unstructured":"Ginocchio VM et al (2013) Efficacy of miglustat in Niemann-Pick C disease: a single centre experience. Mol Genet Metab 110:329\u2013335. doi:\n10.1016\/j.ymgme.2013.07.019","journal-title":"Mol Genet Metab"},{"key":"44_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1172-7-36","volume":"7","author":"B Heron","year":"2012","unstructured":"Heron B et al (2012) Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C Orphanet. J Rare dis 7:36. doi:\n10.1186\/1750-1172-7-36","journal-title":"J Rare dis"},{"key":"44_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10545-014-9718-3","volume":"37","author":"CE Hollak","year":"2014","unstructured":"Hollak CE, Wijburg FA (2014) Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 37:587\u2013598. doi:\n10.1007\/s10545-014-9718-3","journal-title":"J Inherit Metab Dis"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","volume":"96","author":"M Jeyakumar","year":"1999","unstructured":"Jeyakumar M et al (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 96:6388\u20136393","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V97.1.327","volume":"97","author":"M Jeyakumar","year":"2001","unstructured":"Jeyakumar M et al (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97:327\u2013329","journal-title":"Blood"},{"key":"44_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2990.2002.00422.x","volume":"28","author":"M Jeyakumar","year":"2002","unstructured":"Jeyakumar M, Butters TD, Dwek RA, Platt FM (2002) Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 28:343\u2013357","journal-title":"Neuropathol Appl Neurobiol"},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar M et al (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126:974\u2013987","journal-title":"Brain"},{"key":"44_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ana.20242","volume":"56","author":"M Jeyakumar","year":"2004","unstructured":"Jeyakumar M et al (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56:642\u2013649. doi:\n10.1002\/ana.20242","journal-title":"Ann Neurol"},{"key":"44_CR23","doi-asserted-by":"crossref","unstructured":"Kaye EM, Shalish C, Livermore J,Taylor HA, Stevenson RE, Breakefield XO (1997) \u00ce\u00b2-Galactosidase gene mutations in patients With Slowly Progressive GM1 Gangliosidosis. J Child Neurol 12(4):242\u2013247","DOI":"10.1177\/088307389701200404"},{"key":"44_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1046\/j.1471-4159.2004.02381.x","volume":"89","author":"JL Kasperzyk","year":"2004","unstructured":"Kasperzyk JL, El-Abbadi MM, Hauser EC, D'Azzo A, Platt FM, Seyfried TN (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645\u2013653. doi:\n10.1046\/j.1471-4159.2004.02381.x","journal-title":"J Neurochem"},{"key":"44_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","volume":"46","author":"JL Kasperzyk","year":"2005","unstructured":"Kasperzyk JL, d'Azzo A, Platt FM, Alroy J, Seyfried TN (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46:744\u2013751. doi:\n10.1194\/jlr.M400411-JLR200","journal-title":"J Lipid Res"},{"key":"44_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","volume":"51","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ et al (2013) Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 51:116\u2013124. doi:\n10.1016\/j.bcmd.2013.04.005","journal-title":"Blood Cells Mol Dis"},{"key":"44_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymgme.2009.06.005","volume":"98","author":"GH Maegawa","year":"2009","unstructured":"Maegawa GH et al (2009) Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab 98:215\u2013224. doi:\n10.1016\/j.ymgme.2009.06.005","journal-title":"Mol Genet Metab"},{"issue":"Suppl 3","key":"44_CR28","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","volume":"33","author":"M Masciullo","year":"2010","unstructured":"Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G (2010) Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis 33(Suppl 3):S355\u2013S361. doi:\n10.1007\/s10545-010-9186-3","journal-title":"J Inherit Metab Dis"},{"key":"44_CR29","unstructured":"McCormack PL, Goa KL (2003) Miglustat. Drugs 63(22):2427\u20132434; discussion 2435-2426"},{"key":"44_CR30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/mds.20193","volume":"19","author":"U Muthane","year":"2004","unstructured":"Muthane U, Chickabasaviah Y, Kaneski C, Shankar SK, Narayanappa G, Christopher R, Govindappa SS (2004) Clinical features of adult GM1 gangliosidosis: report of three Indian patients and review of 40 cases. Mov Disord 19:1334\u20131341. doi:\n10.1002\/mds.20193","journal-title":"Mov Disord"},{"key":"44_CR31","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23:1138\u20131148. doi:\n10.1038\/mt.2015.62","journal-title":"Mol Ther"},{"key":"44_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2009.11.007","volume":"99","author":"M Pineda","year":"2010","unstructured":"Pineda M et al (2010) Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab 99:358\u2013366. doi:\n10.1016\/j.ymgme.2009.11.007","journal-title":"Mol Genet Metab"},{"key":"44_CR33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.276.5311.428","volume":"276","author":"FM Platt","year":"1997","unstructured":"Platt FM et al (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276:428\u2013431","journal-title":"Science"},{"key":"44_CR34","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.20593","volume":"20","author":"E Roze","year":"2005","unstructured":"Roze E et al (2005) Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 20:1366\u20131369. doi:\n10.1002\/mds.20593","journal-title":"Mov Disord"},{"key":"44_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molcel. 2009.10.021","volume":"36","author":"R Sano","year":"2009","unstructured":"Sano R et al (2009) GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol Cell 36:500\u2013511. doi:\n10.1016\/j.molcel. 2009.10.021","journal-title":"Mol Cell"},{"key":"44_CR36","unstructured":"Suzuki Y., Oshima A., Namba E. (2001) \u03b2-Galactosidase deficiency (\u03b2-galactosidosis) GM1 gangliosidosis and Morquio B disease. In: McGraw-Hill (ed) The Metabolic and Molecular Bases of Inherited Disease, vol 23. vol 1, 8th ed. edn., New-York, pp 3775\u20133809"},{"key":"44_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbrc.2007.12.187","volume":"367","author":"A Takamura","year":"2008","unstructured":"Takamura A et al (2008) Enhanced autophagy and mitochondrial aberrations in murine G (M1)-gangliosidosis. Biochem Biophys Res Commun 367:616\u2013622. doi:\n10.1016\/j.bbrc.2007.12.187","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 1","key":"44_CR38","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1007\/s10545-009-1224-7","volume":"32","author":"CM Tallaksen","year":"2009","unstructured":"Tallaksen CM, Berg JE (2009) Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis 32(Suppl 1):S289\u2013S293. doi:\n10.1007\/s10545-009-1224-7","journal-title":"J Inherit Metab Dis"},{"key":"44_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymgme.2007.08.060","volume":"92","author":"C Tifft","year":"2007","unstructured":"Tifft C, Adams DR, Morgan CP (2007) 55 Miglustat improves function in patients with juvenile GM1 gangliosidosis. Mol Genet Metab 92:24. doi:\n10.1016\/j.ymgme.2007.08.060","journal-title":"Mol Genet Metab"},{"key":"44_CR40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/00498250601094543","volume":"37","author":"A Treiber","year":"2007","unstructured":"Treiber A, Morand O, Clozel M (2007) The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 37:298\u2013314. doi:\n10.1080\/00498250601094543","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"44_CR41","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1007\/s10545-009-1261-2","volume":"32","author":"SB Wortmann","year":"2009","unstructured":"Wortmann SB, Lefeber DJ, Dekomien G, Willemsen MA, Wevers RA, Morava E (2009) Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis 32(Suppl 1):S307\u2013S311. doi:\n10.1007\/s10545-009-1261-2","journal-title":"J Inherit Metab Dis"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-017-0044-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T06:11:11Z","timestamp":1505196671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-017-0044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s11011-017-0044-y","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,3]]}}}